Does inositol signalling have a role in disease susceptibility and drug treatment of bipolar disorder?
Steen
Vidar M
VM
Dr E. Martens' Research Group for Biological Psychiatry and Locus on Neuroscience, Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital, University of Bergen, Norway.
D001714:Bipolar Disorder / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D004198:Disease Susceptibility / Q000378:metabolism* / Q000503:physiopathology; D006801:Humans; D007294:Inositol / Q000378:metabolism*; D008094:Lithium / Q000494:pharmacology / Q000627:therapeutic use; D010744:Phosphoric Monoester Hydrolases / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology
D007294:Inositol; D008094:Lithium; D010744:Phosphoric Monoester Hydrolases; C021822:myo-inositol-1 (or 4)-monophosphatase; C053087:inositol-1,4-bisphosphate 1-phosphatase